Evidence map›Paper›PMID 33043808›Full record

ArticleCell cycle (Georgetown, Tex.)2020

Rapid profiling of G2 phase to mitosis progression by flow cytometry in asynchronous cells.

John Sherman, Ruoning Wang

Open access · hybridAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

John ShermanCenter for Childhood Cancer & Blood Diseases, Hematology/Oncology & BMT, The Research Institute at Nationwide Children's Hospital, Ohio State University , Columbus, OH, USA.ORCID 0000-0002-7998-9979
Ruoning WangCenter for Childhood Cancer & Blood Diseases, Hematology/Oncology & BMT, The Research Institute at Nationwide Children's Hospital, Ohio State University , Columbus, OH, USA.ORCID 0000-0001-9798-8032
Nationwide Children's Hospital · US

Funding

Metabolic programming in TH17 cell differentiationR01AI114581 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI WANG, RUONING · 2015 to 2025
$3.6M
Metabolic reprogramming of tumor microenvironment to maximize immunotherapy for pediatric cancersU01CA232488 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI WANG, RUONING · 2018 to 2018
$3.4M
Oncogenic fusion gene FAX-FKHR in driving metabolic reprogramming in alveolar rhabdomyosarcomaR21CA227926 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI CHANDLER, DAWN S, WANG, RUONING · 2019 to 2020
$364k
NCI NIH HHS U01 CA232488NIAID NIH HHS R01 AI114581
6 · The paper itself

Abstract

The precise control of the cell cycle G2 phase to Mitosis (M phase) transition is central for cell fate determination. The commonly used methods for assessing G2 to M phase progression are based on synchronizing cells and involve perturbation of the natural cell cycle progression. Additionally, these methods are often time-consuming and labor-intensive. Here, we report a flow cytometry-based method that offers a kinetic analysis of G2 to M phase progression in asynchronous cells using nocodazole, 5-Ethynyl-2´-deoxyuridine staining, and histone H3 serine 28 phosphorylation (pH3) staining. Nocodazole is used to collect mitotic cells and prevent their progression into G1, at the same time EdU is added for use as a dump channel during analysis. The remaining cells can then be identified as either G1 or G2/M based on their DNA content. Finally, G2 and M phase cells can be separated based on a mitotic marker, phosphorylation of ser28 on histone H3. While developed to assay G2/M phase progression, this method also resolves G1/S phase progression with no additional steps other than analysis. Compared to double thymidine block, this method does not require extended pre-treatments and is compatible with a greater variety of cell lines, while at the same time offering enhanced consistency and temporal resolution.

Indexed as

Cell CycleCell LineDeoxyuridineFlow CytometryG2 PhaseHistonesHumansKineticsMitosisNocodazolePhosphorylation5-ethynyl-2'-deoxyuridineDeoxyuridineHistonesNocodazolecell cycleG2 phasemethodmitosis

Identifiers

PMID33043808
PMCPMC7714512
OpenAlexW3092047048

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.